Ziņojuma par hinolonu un fluorhinolonu lietošanas riskiem ietekme uz antibiotiku izrakstīšanas tendencēm.
No Thumbnail Available
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Fluorhinoloni ir plaša spektra antibakteriāli līdzekļi (AB), kas tiek lietoti dažādu infekciju ārstēšanai. Sākotnēji, pirms sešdesmit gadiem hinolonu pirmie pārstāvji bija šaura spektra, bet, modificējot struktūru, ar katru nākamo paaudzi tika paplašināts darbības spektrs, uzlabota farmakokinētika un efektivitāte, un tie ir kļuvuši par būtisku AB grupu nopietnu infekciju ārstēšanā gan stacionāros, gan ambulatori. Fluorhinoloni tiek plaši pielietoti arī lauksaimniecībā un veterinārijā, papildus veicinot rezistences attīstību, kas ir viena no būtiskām veselības aprūpes problēmām.
Pēdējā desmitgadē ir pieaudzis ziņojumu daudzums par fluorhinolonu izraisītām blakusparādībām. Lietojušie ir izveidojuši neoficiālas globālas tīmekļa vietnes, tiek ziņots oficiālā veidā zāļu aģentūrām kā FDA, notika EMA rīkota publiskā noklausīšanās par hinolonu un fluorhinolonu AB. To lietošanas drošības profils ir vairākkārtīgi papildināts un atjaunots, un ir iekļauti brīdinājumi par lietošanas riskiem un precizētas indikācijas. Arī ZVA publicēja ziņojumus par fluorhinolonu lietošanas riskiem un izmaiņām indikācijās.
Pētnieciskā darba tēma ir “Ziņojuma par hinolonu un fluorhinolonu lietošanas riskiem ietekme uz antibiotiku izrakstīšanas tendencēm”. Darba mērķis bija izpētīt fluorhinolonu blakusparādību spektra attīstību ASV, ES, LV un noskaidrot, vai ziņojumiem par fluorhinolonu lietošanas riskiem ir ietekme uz turpmākām AB izrakstīšanas tendencēm. Pētījumā tika noskaidrots, ka ir novērojama neliela tendence samazināties ambulatori izrakstīto fluorhinolonu daudzumam, tomēr atšķirība nav statistiski nozīmīga.
Fluoroquinolones are broad spectrum antibacterial agents (AB) used to treat various infections. Initially, sixty years ago, the first members of the quinolones were narrow-spectrum, but by modifying the structure, each successive generation broadened the spectrum of activity, improved pharmacokinetics and efficacy, and they have become an essential group of AB in the treatment of serious infections in both stationary and ambulatory. Fluoroquinolones are also widely used in agriculture and veterinary medicine, in addition to promoting the development of resistance, which is one of the essential health care problems. Reports of fluoroquinolone-related adverse reactions have increased over the last decade. Users have created unofficial global websites, are reported in an official way to the drug agencies like FDA, and a public hearing on quinolone and fluoroquinolone AB was organized by EMA. The safety profile for fluoroquinolone use is updated several times and warnings on the risks of use and specified indications are included. ZVA also published reports on the risks of the use of fluoroquinolones and changes in indications. The topic of the research is “Impact of the report on risks of quinolone and fluoroquinolones on antibiotic prescribing trends”. The aim of this study was to investigate the development of fluoroquinolone side effects spectrum in the US, EU, LV and to determine whether reports of fluoroquinolone use risks have an impact on future AB prescribing trends. The study found that a slight tendency to decrease in outpatient prescribing fluoroquinolones was observed, although difference was not statistically significant.
Fluoroquinolones are broad spectrum antibacterial agents (AB) used to treat various infections. Initially, sixty years ago, the first members of the quinolones were narrow-spectrum, but by modifying the structure, each successive generation broadened the spectrum of activity, improved pharmacokinetics and efficacy, and they have become an essential group of AB in the treatment of serious infections in both stationary and ambulatory. Fluoroquinolones are also widely used in agriculture and veterinary medicine, in addition to promoting the development of resistance, which is one of the essential health care problems. Reports of fluoroquinolone-related adverse reactions have increased over the last decade. Users have created unofficial global websites, are reported in an official way to the drug agencies like FDA, and a public hearing on quinolone and fluoroquinolone AB was organized by EMA. The safety profile for fluoroquinolone use is updated several times and warnings on the risks of use and specified indications are included. ZVA also published reports on the risks of the use of fluoroquinolones and changes in indications. The topic of the research is “Impact of the report on risks of quinolone and fluoroquinolones on antibiotic prescribing trends”. The aim of this study was to investigate the development of fluoroquinolone side effects spectrum in the US, EU, LV and to determine whether reports of fluoroquinolone use risks have an impact on future AB prescribing trends. The study found that a slight tendency to decrease in outpatient prescribing fluoroquinolones was observed, although difference was not statistically significant.
Description
Farmācija
Pharmacy
Veselības aprūpe
Health Care
Pharmacy
Veselības aprūpe
Health Care
Keywords
Fluorhinoloni, hinoloni, blakusefekti, drošības informācija, izrakstīšanas tendences., Fluoroquinolones, quinolones, adverse effects, safety information, prescription trends.